ATE302006T1 - Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen - Google Patents
Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungenInfo
- Publication number
- ATE302006T1 ATE302006T1 AT00940504T AT00940504T ATE302006T1 AT E302006 T1 ATE302006 T1 AT E302006T1 AT 00940504 T AT00940504 T AT 00940504T AT 00940504 T AT00940504 T AT 00940504T AT E302006 T1 ATE302006 T1 AT E302006T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- threomethylphenidate
- hyperactivity disorder
- therapeutic use
- attention deficiency
- Prior art date
Links
- 230000007812 deficiency Effects 0.000 title 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 title 1
- 229960001042 dexmethylphenidate Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000013403 hyperactivity Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960001344 methylphenidate Drugs 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9913458.7A GB9913458D0 (en) | 1999-06-09 | 1999-06-09 | The therapeutic use of d-threo-methylphenidate |
| PCT/GB2000/002234 WO2000074680A1 (en) | 1999-06-09 | 2000-06-08 | The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE302006T1 true ATE302006T1 (de) | 2005-09-15 |
Family
ID=10855048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00940504T ATE302006T1 (de) | 1999-06-09 | 2000-06-08 | Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1185268B1 (de) |
| JP (1) | JP2003501387A (de) |
| AT (1) | ATE302006T1 (de) |
| AU (1) | AU766748B2 (de) |
| CA (1) | CA2376215A1 (de) |
| DE (1) | DE60022033T2 (de) |
| ES (1) | ES2243273T3 (de) |
| GB (1) | GB9913458D0 (de) |
| WO (1) | WO2000074680A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
| US20060189655A1 (en) | 2005-01-20 | 2006-08-24 | David Bar-Or | Methylphenidate derivatives and uses of them |
| US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| JP6983161B2 (ja) | 2015-09-15 | 2021-12-17 | プラクシス・バイオリサーチ・エルエルシー | フェンカンファミンのプロドラッグ |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514451D0 (en) * | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
| US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| MX9805870A (de) * | 1996-01-22 | 1999-01-31 | ||
| US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
-
1999
- 1999-06-09 GB GBGB9913458.7A patent/GB9913458D0/en active Pending
-
2000
- 2000-06-08 AU AU55432/00A patent/AU766748B2/en not_active Ceased
- 2000-06-08 EP EP00940504A patent/EP1185268B1/de not_active Expired - Lifetime
- 2000-06-08 JP JP2001501216A patent/JP2003501387A/ja active Pending
- 2000-06-08 ES ES00940504T patent/ES2243273T3/es not_active Expired - Lifetime
- 2000-06-08 WO PCT/GB2000/002234 patent/WO2000074680A1/en not_active Ceased
- 2000-06-08 AT AT00940504T patent/ATE302006T1/de not_active IP Right Cessation
- 2000-06-08 DE DE60022033T patent/DE60022033T2/de not_active Expired - Fee Related
- 2000-06-08 CA CA002376215A patent/CA2376215A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60022033T2 (de) | 2006-03-30 |
| WO2000074680A1 (en) | 2000-12-14 |
| JP2003501387A (ja) | 2003-01-14 |
| EP1185268A1 (de) | 2002-03-13 |
| EP1185268B1 (de) | 2005-08-17 |
| GB9913458D0 (en) | 1999-08-11 |
| ES2243273T3 (es) | 2005-12-01 |
| CA2376215A1 (en) | 2000-12-14 |
| DE60022033D1 (de) | 2005-09-22 |
| AU766748B2 (en) | 2003-10-23 |
| AU5543200A (en) | 2000-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50002293D1 (de) | Verwendung von csf-1-inhibitoren | |
| DE69738918D1 (de) | Lipoxinverbindungen und deren Verwendung zur Behandlung der Zellenwucherungsstörung | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| ATE322900T1 (de) | Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren | |
| ATE225176T1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| ATE442851T1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
| DE502004005033D1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| DE69326637D1 (de) | 1,4-Disubstituierte Piperazine zur Behandlung von Erkrankungen des Zentralnervensystems und von nervenendokrinen Erkrankungen | |
| EP1231914A4 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| ATE240730T1 (de) | Verwendung von levobupivacaine in gesichtschirugie | |
| ATE302006T1 (de) | Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen | |
| DE60305068D1 (de) | Behandlung von mastalgie mit4-hydroxy-tamoxifen | |
| PT783495E (pt) | Derivados de quinoxalina uteis em terapia | |
| DE69829290D1 (de) | Verwendung von alkanoylcarnitinderivaten zur behandlung von hyperaktivität mit aufmerksamkeitsstörungen | |
| ATE269705T1 (de) | Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen | |
| DE50010234D1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| DE60313785D1 (de) | Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. | |
| DE60128130D1 (de) | Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a | |
| DE60129599D1 (de) | Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b | |
| EA200301221A1 (ru) | Лечение расстройств с гиперактивностью и дефицитом внимания | |
| DE69911436D1 (de) | Die verwendung von r (+)- g(a)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol zur behandlung von obstruktive schlafapnoe | |
| DE50000676D1 (de) | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis | |
| DE19681129D2 (de) | Verwendung des alpha,alpha-Diphenylessigsäure-4-(N-Methyl-Piperidyl)esters als Spasmoanalgetikum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1185268 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |